End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.98 CNY | +3.71% | -8.26% | -37.22% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The firm trades with high earnings multiples: 27.15 times its 2024 earnings per share.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-37.22% | 386M | - | ||
-4.29% | 30.09B | C | ||
+45.72% | 9.91B | C- | ||
+36.80% | 4.52B | B- | ||
-37.06% | 2.39B | C- | ||
-8.01% | 1.62B | - | C+ | |
-30.32% | 1.22B | B | ||
+6.59% | 953M | C | ||
-41.51% | 936M | - | ||
-45.19% | 732M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- 688246 Stock
- Ratings Goodwill E-Health Info Co., Ltd.